Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 5/5/12  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Alshad S. Lalani

Wrong Dr. Alshad S. Lalani?

Director of Strategic Oncology De...

Phone: (914) ***-****  
Email: a***@***.com
Regeneron Pharmaceuticals , Inc.
777 Old Saw Mill River Road
Tarrytown , New York 10591
United States

Company Description: Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for the treatment of...   more

Employment History

Board Memberships and Affiliations


  • PhD
8 Total References
Web References
Editorial Board of Clinical Medicine Insights: Oncology, 5 May 2012 [cached]
Alshad S. Lalani, PhD Director, Translational Oncology, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA
"These preclinical findings suggest that ..., 13 Nov 2011 [cached]
"These preclinical findings suggest that combining REGN910 (SAR307746) and aflibercept in the clinic could be an attractive approach for future clinical research," said Alshad S. Lalani, Ph.D., director of strategic oncology development at Regeneron Pharmaceuticals Inc. in Tarrytown, N.Y. "The rationale is that inhibition of tumor angiogenesis by combining antiangiogenesis treatments could translate into more potent and durable antitumor responses than those observed with single-agent therapy."
"When used alone in animal studies, both REGN910 and aflibercept blocked tumor angiogenesis and growth; however, the combination of the two led to increased tumor hypoxia and consequently to the death of a large percentage of the tumor cells," Lalani said. "Consistent with its ability to promote rapid and widespread tumor cell death in histology, the combination treatment inhibited tumor growth to a significantly greater extent than the single agents in multiple tumor models - colorectal, mammary and prostate. In particular, it caused dramatic tumor regression in the colorectal tumor models. Importantly, no visible evidence of toxicities or enhanced body weight loss was observed following the combination treatment."
In ongoing animal studies, Lalani and colleagues are studying the reasons behind the results with the combined therapy.
To our knowledge, this is the ... [cached]
To our knowledge, this is the first time that the activation of a bioreductive cytotoxic agent in clinical tumor samples has been demonstrated," said Alshad S. Lalani, Ph.D. director of Translational Medicine at Novacea and co-author of the study.
Nearsoft - Nearshore software development outsourcing for product companies [cached]
Alshad S. Lalani, Ph.D., Director, Preclinical & Translational Oncology, Novacea, Inc.
Journal of Translational Medicine | Editorial Board: Dr Alshad Lalani, 11 Aug 2008 [cached]
Alshad LalaniJournal of Translational Medicine | Editorial Board: Dr Alshad Lalani Journal of Translational Medicine
Dr Alshad Lalani, PhD
Editorial Board
Director, Preclinical & Translational Oncology
Other People with the name "Lalani":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.